Drug safety issues affecting a large class of drugs (an example is the increased risk of VTE associated with the use of HRT) provide particular difficulties. In such cases it is important for information provided about the issue to be consistent unless there is clear evidence of a difference between products. Thus there is less likely to be a place for individual companies informing users. In such circumstances communication may be best achieved via a regulatory authority safety bulletin (such as Current Problems in Pharmacovigilance in the United Kingdom) or, if the matter is urgent, a ''Dear Doctor/Pharmacist'' letter may be sent directly by the regulatory authority.
In summary, minimising the risks of ADRs usually requires a variety of measures, and effective communication to professional and lay audiences. The latter issue is dealt with in the next section.
Was this article helpful?